文献速递细菌感染、耐药与抗菌药物医院感染防控

标准化儿童血流感染抗生素试验的结局指标:一项范围综述

Standardizing outcomes in paediatric bloodstream infection antibiotic trials: a scoping review.
PubMed 文献 · Clin Microbiol Infect · 2026-09-15

结果显示结局报告高度异质,临床和微生物学结局分别见于50项(86%)和48项(83%)研究,未报告患者报告结局指标(PROMs),共识别514个不同结局亚类,提示需建立核心结局集。

要点

  • 儿童血流感染抗生素试验结局指标高度异质,共识别514个不同结局亚类。
  • 临床和微生物学结局分别见于86%和83%的研究,安全性结局见于60%。
  • 无研究报告患者报告结局指标(PROMs),需开发整合标准化和以患者为中心的结局核心集。

核心结论

  • 儿童血流感染抗生素试验的结局报告高度可变,且未报告PROMs。
  • 需要开发包含标准化和以患者为中心结局的核心结局集,以提高可比性和支持循证决策。

研究设计与样本

  • 范围综述,检索MEDLINE、Embase、CENTRAL和灰色文献(2010年至2024年12月)。
  • 纳入干预性抗生素试验、临床指南和共识声明及关于PROMs的定性研究。
  • 研究对象为0-18岁儿童包括新生儿,干预为血流感染的抗生素治疗。
  • 由两名评价者独立筛选和提取数据,结局按主题分类。
  • 未进行偏倚风险评估,符合范围综述方法学。

主要发现

  • 新生儿脓毒症是最常研究的疾病(n=28,51%)。
  • 临床和微生物学结局分别报告于50项(86%)和48项(83%)研究,联合结局报告于34项(59%)研究。
  • 安全性结局报告于35项(60%)研究,替代结局于22项(38%),药代动力学指标于12项(21%),成本相关结局于2项(3%),可接受性于1项(2%)。
  • 主观临床结局报告于2项研究(3%),共识别514个不同结局亚类,无研究报告PROMs。

关键数值与推荐

  • 临床结局报告率86%(50/58),微生物学结局83%(48/58),联合结局59%(34/58)。
  • 安全性结局60%(35/58),替代结局38%(22/58),药代动力学21%(12/58),成本相关3%(2/58),可接受性2%(1/58)。
  • 主观临床结局报告于3%(2/58)研究,共识别514个不同结局亚类。

临床怎么用

  • 提示临床医生在解读儿童血流感染抗生素试验时注意结局指标不一致带来的可比性限制。
  • 支持未来试验设计采用核心结局集,并纳入患者报告结局指标。

局限性

  • 未进行偏倚风险评估,符合范围综述方法学。
  • 仅检索2010年至2024年12月发表的文献,可能遗漏更早研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The lack of a standardized framework for outcome measures in paediatric antimicrobial trials for bloodstream infections (BSIs) limits comparability and evidence synthesis. OBJECTIVES: To identify and categorize the outcome measures reported in paediatric antibiotic trials for Staphylococcus aureus, Streptococcus pyogenes, and Gram-negative BSIs to inform future paediatric BSI trial design and core outcome set development, and to identify patient-reported outcome measures (PROMs). DATA SOURCES: MEDLINE, Embase, CENTRAL, and grey literature (2010 to December 2024). STUDY ELIGIBILITY CRITERIA: Interventional antibiotic trials, clinical guidelines and consensus statements for paediatric BSI, and qualitative studies on PROMs. PARTICIPANTS: Children aged 0-18 years, including neonates. INTERVENTIONS: Antibiotic therapy for BSIs, including systemic antibiotic therapy and antibiotic lock therapy. ASSESSMENT OF RISK OF BIAS: Not performed, consistent with scoping review methodology. METHODS OF DATA SYNTHESIS: Two reviewers independently screened and extracted data. Outcomes were categorized thematically. RESULTS: Of 22 622 records (15 960 peer-reviewed; 6662 grey literature), 58 studies met inclusion criteria, comprising 14 424 paediatric and neonatal patients. Neonatal sepsis was the most frequently studied condition (n = 28, 51%). Clinical and microbiological outcomes were reported in 50 (86%) and 48 (83%) studies, respectively, and combined outcomes in 34 (59%). Safety outcomes were reported in 35 (60%) studies, surrogate outcomes in 22 (38%), pharmacokinetic measures in 12 (21%), cost-related outcomes in 2 (3%), and acceptability in 1 (2%). Subjective clinical outcomes were reported in 2 studies (3%). A total of 514 distinct outcome subcategories were identified. No studies reported PROMs. CONCLUSIONS: Outcome reporting in paediatric BSI trials is highly variable, and PROMs were not reported. Developing a core outcome set incorporating standardized and patient-centred outcomes is needed to improve comparability and support evidence-based decision-making.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Wen SCH, de Souza S, Thomas ET, et al. Standardizing outcomes in paediatric bloodstream infection antibiotic trials: a scoping review. Clin Microbiol Infect. 2026. PMID: 42744244. doi:10.1016/j.cmi.2026.09.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。